{"id":5704,"date":"2016-08-19T12:24:26","date_gmt":"2016-08-19T10:24:26","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/en\/?page_id=5704"},"modified":"2016-08-19T12:24:26","modified_gmt":"2016-08-19T10:24:26","slug":"gsdii-or-pompe-disease","status":"publish","type":"page","link":"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/gsdii-or-pompe-disease\/","title":{"rendered":"GSDII or Pompe Disease"},"content":{"rendered":"<p>GSDII (for Glycogen Storage Disease type II), or Pompe Disease, is part of a group of metabolic genetic diseases, glycogen diseases, for which the organism is unable to correctly use sugar as a power source due to an enzyme\u00a0deficiency.<\/p>\n<p>&nbsp;<\/p>\n<h2>Immune Tolerance Induction Study\u00a0\u2014 Myozyme<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>This\u00a0exploratory, open-labeled study of patients with Pompe disease, who have previously received Myozyme (alglucosidase alfa) treatment\u00a0aims at\u00a0evaluating the efficacy, safety and clinical benefit of 2 Immune Tolerance Induction (ITI) regimens in combination with Myozyme.<\/p>\n<p>For more information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00701701\" target=\"_blank\">the immune tolerance induction study webpage<\/a><\/p>\n<h2>NEO-EXT study\u00a0\u2014 LTS 13769<\/h2>\n<ul>\n<li><strong>Reference laboratory:\u00a0<\/strong>Institute of Myology<\/li>\n<\/ul>\n<p>An open-label, multicenter, multinational extension study of the long-term safety and pharmacokinetics of repeated biweekly infusions of NeoGAA in patients with Pompe Disease.<\/p>\n<p>For more information: <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02032524\" target=\"_blank\">NEO-EXT study webpage<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GSDII (for Glycogen Storage Disease type II), or Pompe Disease, is part of a group of metabolic genetic diseases, glycogen diseases, for which the organism is unable to correctly use sugar as a power source due to an enzyme\u00a0deficiency. &nbsp; Immune Tolerance Induction Study\u00a0\u2014 Myozyme Reference laboratory:\u00a0Institute of Myology This\u00a0exploratory, open-labeled study of patients with &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/muscle-diseases\/gsdii-or-pompe-disease\/\">[Read more]<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":4283,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-5704","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=5704"}],"version-history":[{"count":1,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5704\/revisions"}],"predecessor-version":[{"id":5706,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/5704\/revisions\/5706"}],"up":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/pages\/4283"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=5704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}